Immune Persistence and Safety Survey (Cohort Survey) related to the SARS-CoV-2 Booster Vaccination (4th dose) in Japa
Not Applicable
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000047919
- Lead Sponsor
- Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 3441
Inclusion Criteria
Not provided
Exclusion Criteria
Those who are inappropriate as the subject of the survey determined by the principal investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety up to 4 weeks after vaccination of SARS-CoV-2 4th booster vaccination
- Secondary Outcome Measures
Name Time Method Breakthrough infection rate up to 12 months after the final vaccination of SARS-CoV-2 booster vaccination SARS-CoV-2 vaccine 4th booster vaccination Serious adverse events up to 12 months after vaccination (regardless of causality) SARS-CoV-2 vaccine 4th booster vaccination Changes in COVID-19 antibody titer up to 12 months after inoculation (part of the survey subjects)